High Signal, Low Noise
Deep Dives into the Markets
I’ve been observing the investment research ecosystem around here. There is some good work being done. It’s a relief to find pockets of rigor in a market otherwise obsessed with 30-second clips and froth.
I’m leaning toward adding a separate Substack with just my occasional raw investment research and notes for those who prefer their data straight up.
If you want in, let me know. If the interest is any there, any at all, I’ll start shipping some posts.
Here’s an example of a typical screen I’ll run for myself any given morning with my analyst. I’ll follow it up with deeper dives into a name or two. Today, I had some small robotics names I wanted to check in on. Not investment advice, just some thoughts to get you thinking.
____________________________________________
SMALL CAP ROBOTICS QUICK SCREEN - January 28, 2026
Macro Context: US ECON (Growth ↑, Inflation ↓) | VIX: ~15-16 (Investable Bucket) | Pro-Growth Positioning Favored
SERV - Serve Robotics | $13.03 | Mkt Cap $952M
The “physical AI” darling just announced a $29M stock deal to acquire Diligent Robotics, expanding from sidewalk delivery into healthcare. Northland calls it “one of the best investments in physical AI” with 150% upside. Management guiding 10x revenue in 2026 from 2,000 active robots. Still burning ~$25M/quarter but sitting on $210M cash. Nvidia selling its 10% stake spooked sentiment, but the stock is basing out. QUAD 1 tailwind for tech/industrials. Next catalyst: Q4 earnings Mar 5.
Signal: MODERATE LONG | Verdict: RESEARCH
KITT - Nauticus Robotics | $1.28 | Mkt Cap $36M
Underwater robotics play that nearly got delisted twice in 2025. Just regained Nasdaq compliance in December. The Aquanaut subsea robots look interesting for energy infrastructure and deep-sea mining, but this is a company with $5.5M cash against $46M in current liabilities. Q3 revenue hit $1.98M (up 435% YoY), but they lost $6.6M in the quarter. Balance sheet is a prayer, not a plan. May need capital raise at terrible terms.
Signal: WEAK LONG (Speculative) | Verdict: PASS — revisit post-capital raise
ARBE - Arbe Robotics | $1.40 | Mkt Cap $140M
4D imaging radar chipsets for ADAS and autonomous vehicles. Picks-and-shovels play on autonomy with real news flow: won a China state-owned automaker L4 radar deal (production Dec 2026), secured $15.7M convertible bond follow-on, and announced NVIDIA computing integration at CES. But 2024 revenue was $768K—basically pre-revenue. Burning ~$11M/quarter with Dec 2026 bond maturity looming. QUAD 1 tailwind but requires patience.
Signal: WEAK LONG | Verdict: WATCH — revisit on production timeline clarity
RR - Richtech Robotics | $4.94 | Mkt Cap $1.06B
CES 2026 star. Unveiled “Dex” industrial humanoid robot on NVIDIA Jetson Thor and retail went feral—stock up 70% YTD. Real products in commercial deployment: Matradee restaurant bots, ADAM bartenders, DUST-E cleaning robots. HC Wainwright target $6. The catch: FY24 revenue was DOWN 52% to $4.2M (business model pivot), losses ballooned, warrant dilution relentless. Momentum name but extended short-term.
Signal: MODERATE LONG (Momentum) | Verdict: RESEARCH — wait for pullback to $4.00-4.20
STXS - Stereotaxis | $2.56 | Mkt Cap $233M
The “boring robotics” play—medical robotic magnetic navigation for cardiac ablation. Just got FDA clearance for GenesisX, CE Mark for Synchrony, and signed CardioFocus partnership for robotic Pulsed Field Ablation. Unlike others here, this is a real business: Q4 revenue guided >$9M, full-year growth >20%, recurring revenue at $5.6M/quarter with 67% gross margins. MAGiC catheter generating >$300K in first two months. High insider ownership (30%) is a nice tell. Healthcare underweight in QUAD 1 but medtech marches to its own beat.
Signal: MODERATE LONG | Verdict: RESEARCH — best risk/reward in the group
SUMMARY
SERV ($13.03) - Mod Long — QUAD Tailwind — Catalyst Mar 5 — RESEARCH
KITT ($1.28) - Weak Long — QUAD Neutral — Catalyst Mar — PASS
ARBE ($1.40) - Weak Long — QUAD Tailwind — Catalyst Mar 4 — WATCH
RR ($4.94) - Mod Long — QUAD Tailwind — Catalyst Done — RESEARCH
STXS ($2.56) - Mod Long — QUAD Neutral — Catalyst Mar — RESEARCH
Bottom Line:
Deep Dive: STXS - Best fundamentals of the bunch. Real revenue, FDA tailwinds, insider alignment.
Momentum Play: RR - If chasing the humanoid theme, this has actual products. Wait for pullback.
Watch: ARBE - China L4 win is meaningful if it materializes. Revisit Q2.
Pass: KITT - Balance sheet is a mess. Too much survival risk.
